英语资讯
News

国际英语新闻:EU concludes exploratory talks to secure Valneva's potential COVID-19 vaccine

Source: Xinhuanet    2021-01-13  我要投稿   论坛   Favorite  

BRUSSELS, Jan. 12 (Xinhua) -- The European Commission concluded exploratory talks on Tuesday with European biotechnology company Valneva with a view to purchasing up to 60 million doses of its COVID-19 vaccine once it proves to be safe and effective.

The conclusion of the talks came hot on the heels of a number of contracts the Commission had already signed with producers like AstraZeneca, Sanofi-GSK, Janssen, BioNtech-Pfizer, CureVac and Moderna. Exploratory talks have also been concluded with U.S. pharmaceutical company Novavax to secure 200 million doses of its vaccine candidate.

Stella Kyriakides, European commissioner for health and food safety, said that by securing a diversified range of vaccines, the EU was maximizing the chances of making sure that all citizens can have access to COVID-19 vaccines by the end of 2021.

Headquartered in France, Valneva develops a traditional inactivated coronavirus vaccine, the only such candidate in clinical trials in Europe.

On Dec. 16, 2020, Valneva announced the initiation of a Phase 1/2 clinical study for its VLA2001 COVID-19 vaccine candidate. The study was conducted in Britain. The company expects initial regulatory approval in the fourth quarter of 2021.

As the world is struggling to contain the pandemic, vaccination is underway in some countries with the already-authorized coronavirus vaccines.

Meanwhile, 236 candidate vaccines are still being developed worldwide -- 63 of them in clinical trials -- in countries including Germany, China, Russia, Britain and the United States, according to information released by the World Health Organization on Jan. 12.


将本页收藏到:
上一篇:国际英语新闻:Trump calls looming impeachment against him "ridiculous"
下一篇:国际英语新闻:Japan's PM set to expand emergency to more prefectures

最新更新
论坛精彩内容
网站地图 - 学习交流 - 恒星英语论坛 - 关于我们 - 广告服务 - 帮助中心 - 联系我们
Copyright ©2006-2007 www.Hxen.com All Rights Reserved